A5046120768- Dementia and Cognitive Impairment Research
- Alzheimer's disease research and treatments
- Amyotrophic Lateral Sclerosis Research
- Functional Brain Connectivity Studies
- Parkinson's Disease Mechanisms and Treatments
- Neurobiology of Language and Bilingualism
- Advanced Neuroimaging Techniques and Applications
- Neurological Disease Mechanisms and Treatments
- Neurological diseases and metabolism
- Memory and Neural Mechanisms
- Prion Diseases and Protein Misfolding
- Neuroinflammation and Neurodegeneration Mechanisms
- Spatial Neglect and Hemispheric Dysfunction
- Advanced MRI Techniques and Applications
- Genetic Neurodegenerative Diseases
- EEG and Brain-Computer Interfaces
- Epilepsy research and treatment
- Neurological disorders and treatments
- Health, Environment, Cognitive Aging
- Action Observation and Synchronization
- Neurogenetic and Muscular Disorders Research
- S100 Proteins and Annexins
- Cholinesterase and Neurodegenerative Diseases
- Genetic Associations and Epidemiology
- Neural dynamics and brain function
University Memory and Aging Center
2016-2025
University of California, San Francisco
2016-2025
Global Brain Health Institute
2017-2025
Trinity College Dublin
2019-2025
San Francisco VA Medical Center
2004-2024
Center for Neurosciences
2013-2024
The University of Texas Health Science Center at Houston
2024
University of Florida
2024
Alzheimer’s Disease Neuroimaging Initiative
2012-2024
Amsterdam University of Applied Sciences
2024
Ubiquitin-positive, tau- and α-synuclein–negative inclusions are hallmarks of frontotemporal lobar degeneration with ubiquitin-positive amyotrophic lateral sclerosis. Although the identity ubiquitinated protein specific to either disorder was unknown, we showed that TDP-43 is major disease in both disorders. Pathologic hyper-phosphorylated, ubiquitinated, cleaved generate C-terminal fragments recovered only from affected central nervous system regions, including hippocampus, neocortex,...
Based on the recent literature and collective experience, an international consortium developed revised guidelines for diagnosis of behavioural variant frontotemporal dementia. The validation process retrospectively reviewed clinical records compared sensitivity proposed earlier criteria in a multi-site sample patients with pathologically verified lobar degeneration. According to criteria, 'possible' dementia requires three six clinically discriminating features (disinhibition,...
This article provides a classification of primary progressive aphasia (PPA) and its 3 main variants to improve the uniformity case reporting reliability research results. Criteria for PPA--nonfluent/agrammatic, semantic, logopenic--were developed by an international group PPA investigators who convened on occasions operationalize earlier published clinical descriptions subtypes. Patients are first diagnosed with then divided into based specific speech language features characteristic each...
Current criteria for the clinical diagnosis of pathologically confirmed corticobasal degeneration (CBD) no longer reflect expanding understanding this disease and its clinicopathologic correlations. An international consortium behavioral neurology, neuropsychology, movement disorders specialists developed new based on consensus a systematic literature review. Clinical diagnoses (early or late) were identified 267 nonoverlapping CBD cases from published reports brain banks. Combined with...
Abstract We performed a comprehensive cognitive, neuroimaging, and genetic study of 31 patients with primary progressive aphasia (PPA), decline in language functions that remains isolated for at least 2 years. Detailed speech evaluation was used to identify three different clinical variants: nonfluent (NFPA; n = 11), semantic dementia (SD; 10), third variant termed logopenic (LPA; 10). Voxel‐based morphometry (VBM) on MRIs showed that, when all PPA were analyzed together, the left...
<b><i>Objective: </i></b> To update the 1994 practice parameter for diagnosis of dementia in elderly. <b><i>Background:</i></b> The AAN previously published a on 1994. New research and clinical developments warrant an some aspects diagnosis. <b><i>Methods:</i></b> Studies English from 1985 through 1999 were identified that addressed four questions: 1) Are current criteria reliable? 2) diagnostic able to establish prevalent dementias elderly? 3) Do laboratory tests improve accuracy dementing...
SEE SARAZIN ET AL DOI101093/BRAIN/AWW041 FOR A SCIENTIFIC COMMENTARY ON THIS ARTICLE: The advent of the positron emission tomography tracer (18)F-AV1451 provides unique opportunity to visualize regional distribution tau pathology in living human brain. In this study, we tested hypothesis that is closely linked symptomatology and patterns glucose hypometabolism Alzheimer's disease, contrast more diffuse amyloid-β pathology. We included 20 patients meeting criteria for probable disease...
Resting-state or intrinsic connectivity network functional magnetic resonance imaging provides a new tool for mapping large-scale neural function and dysfunction. Recently, we showed that behavioural variant frontotemporal dementia Alzheimer's disease cause atrophy within two major networks, an anterior 'Salience Network' (atrophied in dementia) posterior 'Default Mode disease). These networks exhibit anti-correlated relationship with each other the healthy brain. The diseases also feature...
<b><i>Objective:</i></b> To identify and compare the patterns of cerebral atrophy associated with two clinical variants frontotemporal lobar degeneration (FTLD): dementia (FTD) semantic (SemD). <b><i>Methods:</i></b> Twenty patients FTLD were classified as having FTD (N = 8) or SemD 12) based on current criteria. Both groups showed a similar spectrum behavioral abnormalities, indicated by neuropsychiatric inventory. T1-weighted MRI was obtained for each patient 20 control subjects. The...
Background Proteins pathogenic in Alzheimer's disease (AD) were extracted from neurally derived blood exosomes and quantified to develop biomarkers for the staging of sporadic AD. Methods Blood obtained at one time-point patients with AD (n = 57) or frontotemporal dementia (FTD) 16), two time-points others 24) when cognitively normal 1 10 years later diagnosed enriched neural sources by immunoabsorption. AD-pathogenic exosomal proteins enzyme-linked immunosorbent assays. Results Mean levels...
Abstract In this clinical study, the cerebrospinal fluid (CSF) level of a Novemberel form β‐amyloid peptide (Aβ) extending to position 42 (Aβ ) was determined in patients with Alzheimer's disease (AD) as well controls. addition measurement CSF Aβ levels, total peptides, microtubule‐associated protein τ, and apolipoprotein E (ApoE) genotype were also assessed. It is interesting that levels found be significantly lower AD relative controls, whereas not. has recently been shown preferentially...
Patients with frontotemporal dementia (FTD) no known diagnosis of ALS or family history were clinically and electrophysiologically assessed for the presence ALS. Of 36 patients studied, five met criteria a definite two had EMG findings suggestive denervation in one limb. An additional prominent fasciculations six other trouble swallowing but all normal results on studies. One study progressed to over course 1 year.